{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-26-000377","form_type":"8-K","ticker":"EBRCZ","cik":"0001347123","company_name":"EBR Systems, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.896320+00:00","generated_at":"2026-05-16T10:38:13.584096+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EBR Systems reports Q4 2025 preliminary rev ~$900K; WiSE implants double QoQ, clinical studies advance","bullets":["Preliminary Q4 revenue $870K-$935K; FY2025 revenue $1,552K-$1,617K (unaudited, subject to audit adjustments).","Commercial WiSE implants doubled QoQ to 18 in Q4, reaching 30 total for the year; 9 new purchase agreements signed.","WiSE-UP post-approval study enrolled 4 patients; TLC-AU feasibility study enrolled first patient in Australia.","11 additional physicians trained in Q4, bringing total trained to 33 across 21 centers."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-26-000377","json":"https://secwatch.observer/filing/0001214659-26-000377.json","markdown":"https://secwatch.observer/filing/0001214659-26-000377.md","text":"https://secwatch.observer/filing/0001214659-26-000377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347123/000121465926000377/0001214659-26-000377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347123/000121465926000377/b1122638k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:38:13.584096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}